Clearstead Trust LLC Has $1.40 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Clearstead Trust LLC boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,280 shares of the biopharmaceutical company’s stock after purchasing an additional 288 shares during the period. Clearstead Trust LLC’s holdings in Alnylam Pharmaceuticals were worth $1,396,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ALNY. SVB Wealth LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at about $27,000. Atlantic Union Bankshares Corp bought a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $30,000. Ameritas Advisory Services LLC acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $42,000. AlphaQuest LLC acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $43,000. Finally, Larson Financial Group LLC raised its holdings in Alnylam Pharmaceuticals by 77.7% during the 1st quarter. Larson Financial Group LLC now owns 199 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 87 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,405 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $635,130.25. Following the completion of the sale, the executive vice president owned 27,438 shares in the company, valued at $12,403,347.90. The trade was a 4.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Pushkal Garg sold 3,022 shares of the company’s stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the transaction, the executive vice president directly owned 20,221 shares in the company, valued at $9,129,377.08. The trade was a 13.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 66,696 shares of company stock valued at $30,430,694. Company insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. BMO Capital Markets upped their price objective on shares of Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a research note on Friday, September 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a research report on Wednesday, October 8th. Bank of America lifted their price objective on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Wells Fargo & Company upped their target price on Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the company an “equal weight” rating in a research report on Tuesday. Finally, Morgan Stanley raised their target price on Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research note on Monday, October 6th. Twenty-three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $482.17.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $453.97 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a market cap of $59.98 billion, a PE ratio of -183.79 and a beta of 0.30. The stock has a 50-day moving average of $458.86 and a 200-day moving average of $381.74. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.